Hepion Pharmaceuticals, Inc. (HEPA) |
|
0.73 0.015 (2.08%)
|
03-22 11:39 |
|
Open: |
0.7151 |
Pre. Close: |
0.7151 |
|
High:
|
0.7364 |
Low:
|
0.7003 |
|
Volume:
|
20,406 |
Market Cap:
|
56(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:16:48 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.92 One year: 1.02 |
| Support: |
Support1: 0.66 Support2: 0.54 |
| Resistance: |
Resistance1: 0.79 Resistance2: 0.87 |
| Pivot: |
0.76  |
| Moving Average: |
MA(5): 0.72 MA(20): 0.76
MA(100): 0.58  MA(250): 0.65 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 21.7 %D(3): 24.5 |
| RSI: |
RSI(14): 44 |
| 52-week: |
High: 1.33 Low: 0.25 |
| Average Vol(K): |
3-Month: 771 (K) 10-Days: 108 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HEPA ] has closed above bottom band by 20.4%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.74 - 0.75 |
0.75 - 0.75 |
|
Low:
|
0.69 - 0.7 |
0.7 - 0.7 |
|
Close:
|
0.71 - 0.72 |
0.72 - 0.72 |
|
Company Description |
|
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. |
Headline News |
Thu, 16 Mar 2023
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI ... - Yahoo Finance
Thu, 09 Mar 2023
Should You Add Hepion Pharmaceuticals Inc (HEPA) Stock to Your Portfolio Thursday? - InvestorsObserver
Thu, 02 Mar 2023
EPO Decision to Grant European Patent for Rencofilstat Further ... - GlobeNewswire
Thu, 02 Mar 2023
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 ... - GlobeNewswire
Wed, 01 Mar 2023
Do Traders Think Hepion Pharmaceuticals Inc (HEPA) Can Keep Climbing Wednesday? - InvestorsObserver
Mon, 27 Feb 2023
Will Hepion Pharmaceuticals Inc (HEPA) Stay at the Top of the Healthcare Sector? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
76 (M) |
| Shares Float |
76 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
9.4 (%) |
|
Shares Short
|
717 (K) |
|
Shares Short P.Month
|
906 (K) |
Stock Financials |
|
EPS
|
-0.57 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.75 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-30.9 |
|
Return on Equity (ttm)
|
-55.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.59 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-38 (M) |
|
Levered Free Cash Flow
|
-24 (M) |
Stock Valuations |
|
PE Ratio
|
-1.27 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.94 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-02 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
